World Expert on Liver Disease Joins the Scientific Advisory Board of Medgenics

[Guest guest]

http://www.earthtimes.org/articles/show/world-expert-on-liver-disease,1076755.sh\

tml#

Earthtimes.org (Press Release)

--------------------------------------------------------------------------------

World Expert on Liver Disease Joins the Scientific Advisory Board of Medgenics

Posted on : 2009-12-07 | Author : Medgenics

MISGAV, Israel & LONDON - (Business Wire) Medgenics (AIM: MEDG and MEDU), the

biopharmaceutical company that creates implantable therapeutic protein producing

Biopumps, announced today that Dr. Bruce R. Bacon was appointed to the

Scientific Advisory Board of the Company.

Dr. Bacon is a former President of the American Association for the Study of

Liver Diseases (AASLD) and a recognised World expert on Hepatitis. Dr. Bacon is

the F. King, MD Endowed Chair in Gastroenterology, Professor of Internal

Medicine, and Director of the Division of Gastroenterology and Hepatology at

Saint Louis University School of Medicine in St. Louis, Missouri. The potential

treatment of Hepatitis using the Company’s patented INFRADURE technology is one

of the core projects that the Company is seeking to commercialise. Medgenics

reported consistently promising and unprecedented results from the safety and

efficacy clinical trial of its EPODURE Biopumps for sustained anaemia treatment

from a single administration, in progress since September 2008. Biopumps are

made from tissue taken by needle biopsy taken from under the patient’s own skin

and processed to become implantable biofactories to provide the required

therapeutic protein for many months. The INFRADURE technology has been similarly

used to create implantable Biopumps that produce Interferon Alpha for months and

will offer a significant addition to the physician’s Hepatitis armamentarium to

treat this scourge of a disease.

Dr. Eugene Bauer, Chairman of Medgenics commented:

“We are delighted to welcome Dr. Bacon to Medgenics. As one of the world’s top

experts in Hepatitis C, he brings a wealth of experience and influence to the

company. Hepatitis is one of the core areas of treatment that we are seeking to

commercialise. Having an expert of Dr. Bacon’s calibre is essential as we move

into the clinic with the exciting new approach to treatment that our INFRADURE

technology offers. Our ability to attract leading figures such as Dr. Bacon

demonstrates the growing stature of Medgenics in the global market for

therapeutic protein delivery. I and the rest of the Board look forward to

working with him as we continue to develop Medgenics.”

Dr. Pearlman, CEO of Medgenics commented:

“The appointment of Dr. Bacon is another important addition to the senior team

at Medgenics. Coming in the wake of the signing of a hemophilia development

agreement with a major international biopharmaceutical company, Dr. Bacon’s

appointment is a further strong vote of confidence for Medgenics and our

INFRADURE approach to interferon alpha therapy in the treatment of Hepatitis C.”

About Medgenics:

Medgenics is a clinical-stage biopharmaceutical company developing its unique

tissue-based Biopump platform technology using the patient’s own skin to provide

sustained-action protein therapy for the treatment of a range of chronic

diseases. The Company currently has three products in development based on this

technology and addressing the indications of:

- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)

- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)

- Hemophilia - using a Biopump to produce clotting Factor VIII

The Company's Phase I/II clinical trial using EPODURE to treat anaemia in

patients with chronic kidney disease, has demonstrated proof of concept of the

Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for

six months or more, EPODURE Biopumps have already provided effective anaemia

treatment in most of these patients for 6-12 months, even at the low

administered dose.

Medgenics intends to develop its innovative products and bring them to market

via multiple strategic partnerships with major pharmaceutical and/or medical

device companies. In addition to treatments for Anaemia, Hepatitis-C,

Hemophilia, Medgenics plans to develop and/or out-license a pipeline of future

Biopump products targeting the large and rapidly growing global protein therapy

market, which is forecast to reach US $87 billion by 2010. Other potential

applications of Biopumps producing various proteins include multiple sclerosis,

arthritis, pediatric growth hormone deficiency, obesity, and diabetes.

Medgenics, Inc.

Dr. L. Pearlman

Phone: +972 4 902 8900

or

Grayling (Financial PR - UK)

Shillington

Phone: +44 7900 053 536

jonathan.shillington@...

or

Grayling (Investor Relations - US)

Alistair

Phone: +1 646 284 9472

or

Wolf-Creutzfeldt

lwolf-creutzfeldt@...

or

Blomfield Corporate Finance Limited (Nominated Adviser)

Pinner

Phone: +44207 444 0500

or

Alan MacKenzie

Phone: +44207 444 0500

or

SVS Securities plc (Broker)

Ian Callaway

Phone: +44 207 638 5600

Press Release Print Source :

http://www.earthtimes.org/articles/show/world-expert-on-liver-disease,1076755.sh\

tml

© 2009 earthtimes.org. .

[Guest guest]

http://www.earthtimes.org/articles/show/world-expert-on-liver-disease,1076755.sh\

tml#

Earthtimes.org (Press Release)

--------------------------------------------------------------------------------

World Expert on Liver Disease Joins the Scientific Advisory Board of Medgenics

Posted on : 2009-12-07 | Author : Medgenics

MISGAV, Israel & LONDON - (Business Wire) Medgenics (AIM: MEDG and MEDU), the

biopharmaceutical company that creates implantable therapeutic protein producing

Biopumps, announced today that Dr. Bruce R. Bacon was appointed to the

Scientific Advisory Board of the Company.

Dr. Bacon is a former President of the American Association for the Study of

Liver Diseases (AASLD) and a recognised World expert on Hepatitis. Dr. Bacon is

the F. King, MD Endowed Chair in Gastroenterology, Professor of Internal

Medicine, and Director of the Division of Gastroenterology and Hepatology at

Saint Louis University School of Medicine in St. Louis, Missouri. The potential

treatment of Hepatitis using the Company’s patented INFRADURE technology is one

of the core projects that the Company is seeking to commercialise. Medgenics

reported consistently promising and unprecedented results from the safety and

efficacy clinical trial of its EPODURE Biopumps for sustained anaemia treatment

from a single administration, in progress since September 2008. Biopumps are

made from tissue taken by needle biopsy taken from under the patient’s own skin

and processed to become implantable biofactories to provide the required

therapeutic protein for many months. The INFRADURE technology has been similarly

used to create implantable Biopumps that produce Interferon Alpha for months and

will offer a significant addition to the physician’s Hepatitis armamentarium to

treat this scourge of a disease.

Dr. Eugene Bauer, Chairman of Medgenics commented:

“We are delighted to welcome Dr. Bacon to Medgenics. As one of the world’s top

experts in Hepatitis C, he brings a wealth of experience and influence to the

company. Hepatitis is one of the core areas of treatment that we are seeking to

commercialise. Having an expert of Dr. Bacon’s calibre is essential as we move

into the clinic with the exciting new approach to treatment that our INFRADURE

technology offers. Our ability to attract leading figures such as Dr. Bacon

demonstrates the growing stature of Medgenics in the global market for

therapeutic protein delivery. I and the rest of the Board look forward to

working with him as we continue to develop Medgenics.”

Dr. Pearlman, CEO of Medgenics commented:

“The appointment of Dr. Bacon is another important addition to the senior team

at Medgenics. Coming in the wake of the signing of a hemophilia development

agreement with a major international biopharmaceutical company, Dr. Bacon’s

appointment is a further strong vote of confidence for Medgenics and our

INFRADURE approach to interferon alpha therapy in the treatment of Hepatitis C.”

About Medgenics:

Medgenics is a clinical-stage biopharmaceutical company developing its unique

tissue-based Biopump platform technology using the patient’s own skin to provide

sustained-action protein therapy for the treatment of a range of chronic

diseases. The Company currently has three products in development based on this

technology and addressing the indications of:

- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)

- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)

- Hemophilia - using a Biopump to produce clotting Factor VIII

The Company's Phase I/II clinical trial using EPODURE to treat anaemia in

patients with chronic kidney disease, has demonstrated proof of concept of the

Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for

six months or more, EPODURE Biopumps have already provided effective anaemia

treatment in most of these patients for 6-12 months, even at the low

administered dose.

Medgenics intends to develop its innovative products and bring them to market

via multiple strategic partnerships with major pharmaceutical and/or medical

device companies. In addition to treatments for Anaemia, Hepatitis-C,

Hemophilia, Medgenics plans to develop and/or out-license a pipeline of future

Biopump products targeting the large and rapidly growing global protein therapy

market, which is forecast to reach US $87 billion by 2010. Other potential

applications of Biopumps producing various proteins include multiple sclerosis,

arthritis, pediatric growth hormone deficiency, obesity, and diabetes.

Medgenics, Inc.

Dr. L. Pearlman

Phone: +972 4 902 8900

or

Grayling (Financial PR - UK)

Shillington

Phone: +44 7900 053 536

jonathan.shillington@...

or

Grayling (Investor Relations - US)

Alistair

Phone: +1 646 284 9472

or

Wolf-Creutzfeldt

lwolf-creutzfeldt@...

or

Blomfield Corporate Finance Limited (Nominated Adviser)

Pinner

Phone: +44207 444 0500

or

Alan MacKenzie

Phone: +44207 444 0500

or

SVS Securities plc (Broker)

Ian Callaway

Phone: +44 207 638 5600

Press Release Print Source :

http://www.earthtimes.org/articles/show/world-expert-on-liver-disease,1076755.sh\

tml

© 2009 earthtimes.org. .